Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Narrative (Details)

v3.24.2.u1
Fair Value Measurements - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Mar. 28, 2024
shares
Jun. 30, 2024
USD ($)
$ / shares
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jun. 30, 2024
USD ($)
$ / shares
Jun. 30, 2023
USD ($)
Mar. 31, 2024
$ / shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Net proceeds from the sale   $ (112,046) $ 0   $ (112,046) $ 0  
AVTX-501              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Maximum aggregate milestone payment       $ 20,000      
AVTX-007 | Milestone One              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Maximum aggregate milestone payment       6,250      
AVTX-007 | Milestone Two              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Maximum aggregate milestone payment       67,500      
AVTX-611              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Maximum aggregate milestone payment       20,000      
Derivative liability | AVTX-501              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Initial valuation of warrant liability       $ 3,500 3,800    
Derivative liability | AVTX-501 | Measurement Input, Probability Of Success              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input       0.23      
Derivative liability | AVTX-501 | Expected term (in years)              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input, term       3 years 3 months 18 days      
Derivative liability | AVTX-007              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Initial valuation of warrant liability       $ 1,300 $ 6,900    
Derivative liability | AVTX-007 | Measurement Input, Probability Of Success              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input       0.17      
Derivative liability | AVTX-007 | Expected term (in years)              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Derivative liability, measurement input, term       6 years 6 months      
Derivative liability | AVTX-007 | Measurement Input, Sales Forecast Peak              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Net proceeds from the sale       $ 1,800,000      
Derivative liability | AVTX-501 And AVTX-007              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Initial valuation of warrant liability       4,800      
ES Therapeutics, LLC | Derivative liability              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Initial valuation of warrant liability       $ 5,000      
Warrant liability              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Closing stock price (in dollars per share) | $ / shares   $ 12.47     $ 12.47   $ 21.75
Warrant liability | Private Placement              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Sale of stock (in shares) | shares 11,967,526            
Series C Preferred Stock | Private Placement              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Sale of stock (in shares) | shares 19,946